Page last updated: 2024-08-24

plerixafor and Uterine Cervical Neoplasms

plerixafor has been researched along with Uterine Cervical Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chaudary, N; Han, K; Hill, RP; Lecavalier-Barsoum, M; Milosevic, M; Pintilie, M1
Baleux, F; Brule, S; Charnaux, N; Friand, V; Gattegno, L; Sutton, A1

Other Studies

2 other study(ies) available for plerixafor and Uterine Cervical Neoplasms

ArticleYear
Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
    British journal of cancer, 2019, Volume: 121, Issue:3

    Topics: Animals; Benzylamines; Chemokine CXCL12; Chemoradiotherapy; Cyclams; Female; Heterocyclic Compounds; Humans; Mice; Mice, Inbred C57BL; Myeloid Cells; Receptors, CXCR4; Signal Transduction; Uterine Cervical Neoplasms

2019
Glycosaminoglycans and syndecan-4 are involved in SDF-1/CXCL12-mediated invasion of human epitheloid carcinoma HeLa cells.
    Biochimica et biophysica acta, 2009, Volume: 1790, Issue:12

    Topics: Anthracenes; Benzylamines; Carcinoma in Situ; Cell Movement; Chemokine CXCL12; Cyclams; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Glycosaminoglycans; HeLa Cells; Heterocyclic Compounds; Humans; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Signal Transduction; Syndecan-4; Uterine Cervical Neoplasms

2009